Inhibrx Secures $325M Loan Amendment as Clinical Trials Advance
Event summary
- Inhibrx amended its loan agreement with Oxford Finance LLC for an additional $325M, receiving $100M upfront in July 2026.
- The company plans to announce progression-free survival (PFS) data from the INBRX-106 Phase 2 trial in HNSCC in Q3 2026.
- Inhibrx initiated two additional Phase 1 cohorts for ozekibart (INBRX-109) in colorectal cancer during Q2 2026.
- The FDA accepted the BLA for ozekibart in conventional chondrosarcoma with a PDUFA goal date of April 14, 2027.
The big picture
Inhibrx's strategic maneuvering—securing substantial financing and advancing multiple clinical programs—positions it to navigate the capital-intensive biopharmaceutical landscape. The company's focus on regulatory interactions and data readouts underscores its push toward potential commercial milestones, amid a competitive oncology market where differentiated therapies command premium valuations.
What we're watching
- Financial Flexibility
- How Inhibrx will deploy the remaining $225M from the loan amendment to support its clinical pipeline and potential commercialization efforts.
- Regulatory Pathway
- Whether the FDA meeting in Q4 2026 will pave the way for an accelerated approval pathway for ozekibart in fourth-line CRC.
- Clinical Data Readouts
- The pace at which interim results from the additional Phase 1 cohorts for ozekibart in colorectal cancer will influence its development strategy.